Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome

Abstract Introduction Imeglimin, a glucose‐lowering agent targeting mitochondrial bioenergetics, decreases reactive oxygen species (ROS) overproduction and improves glucose homeostasis. We investigated whether this is associated with protective effects on metabolic syndrome‐related left ventricular...

Full description

Bibliographic Details
Main Authors: Marianne Lachaux, Matthieu Soulié, Mouad Hamzaoui, Anaëlle Bailly, Lionel Nicol, Isabelle Rémy‐Jouet, Sylvanie Renet, Cathy Vendeville, Pascale Gluais‐Dagorn, Sophie Hallakou‐Bozec, Christelle Monteil, Vincent Richard, Paul Mulder
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
cardiomyopathy
imeglimin
rat
type‐2 diabetes
Online Access:https://doi.org/10.1002/edm2.128

Internet

https://doi.org/10.1002/edm2.128

Similar Items